Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Pulmonx CorporationNASDAQ: LUNG

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue dips below year-ago levels

Q1 FY2026 revenue of $20.59M fell 8.7% year over year, behind the +1.2% change in trailing-twelve-month revenue. Sequentially, it fell 8.9% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $91.03M (+0.6%) for the fiscal year ending Dec 2026, a slowdown from the +8.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.59M-8.9% QoQ
Last fiscal yearDec 2025
$90.5M+8.0% YoY
LTMMar 2026
$88.55M+1.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.7%-6.1%+2.5 pp
1 year+8.0%+0.6%-7.4 pp
3-year CAGR+19.0%+6.5%-12.5 pp
5-year CAGR+8.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
90.5M USD
Year-over-year change
+8.0%
4-year CAGR
+16.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's LTM Mar 2026 revenue of $88.55M is the 3rd highest of the 10 companies compared; the peer median is $9.14M.
  • Its year-over-year change of +1.2% is the 5th highest of 6, against a peer median of +30.7%.
  • Over three fiscal years its annual growth of +19.0% compares with a peer median of +24.7%.
LUNG Competitors Peer median
Revenue for LUNG and competitors
Company Period LTM YoY 3-year CAGR
VXRTVaxart, Inc.LTM Mar 2026$255.61M +439.3%+1204.0%
ASRTAssertio Holdings, Inc.LTM Mar 2026$102.16M -14.2%-8.7%
LUNGPulmonx CorporationLTM Mar 2026$88.55M +1.2%+19.0%
TELATELA Bio, Inc.LTM Jun 2026$79.91M +6.1%+24.7%
HYPRHyperfine, Inc.LTM Mar 2026$15.33M +30.7%+25.8%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$9.14M +106.7%-8.6%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ——
IMUXImmunic, Inc.LTM Mar 2026$0 ——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 ——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 ——
Peer median (excluding LUNG) $9.14M+30.7%+24.7%

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.42M53.66M68.68M83.79M90.5M
Cost of Revenue12.79M13.8M17.92M21.79M23.36M
Gross Profit35.63M39.87M50.75M62M67.14M
Gross Margin73.6%74.3%73.9%74.0%74.2%
Research & Development13.06M15.4M18.08M17.57M19.49M
Selling, General & Admin69.87M83.11M94.61M102.14M101.31M
Operating Expenses82.93M98.5M112.69M119.71M120.8M
Depreciation & Amortization867K1.51M1.95M1.59M1.05M
EBITDA(46.62M)(55.99M)(55.09M)(50.79M)(49.17M)
EBITDA Margin-96.3%-104.3%-80.2%-60.6%-54.3%
Operating Income(47.3M)(58.64M)(61.94M)(57.7M)(53.66M)
Operating Margin-97.7%-109.3%-90.2%-68.9%-59.3%
Interest Income400K1.53M5.57M5.06M2.65M
Interest Expense829K1.07M3.23M3.51M3.16M
Other Income / Expenses(1.01M)67K1.66M1.81M286K
Income Before Tax(48.32M)(58.57M)(60.27M)(55.89M)(53.38M)
Pre-Tax Margin-99.8%-109.1%-87.8%-66.7%-59.0%
Income Tax Expense343K353K571K500K626K
Net Income(48.66M)(58.92M)(60.84M)(56.39M)(54M)
Net Margin-100.5%-109.8%-88.6%-67.3%-59.7%
EPS (Basic)(1.35)(1.59)(1.60)(1.44)(1.33)
EPS (Diluted)(1.35)(1.59)(1.60)(1.44)(1.33)
Weighted Avg Shares36.13M37.1M37.97M39.11M40.69M
Weighted Avg Shares (Diluted)36.13M37.1M37.97M39.11M40.69M

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.